C-reactive protein (CRP) tests are blood tests that are performed to measure C-reactive protein levels. C-reactive protein (CRP) is a protein released by the liver, and its levels rise when the body is inflamed. Infections and disorders that cause inflammation, such as cancers, cardiovascular diseases, arthritis, and others, are detected and tracked using C-reactive tests. This test predicts the risks of a person having a heart attack or a stroke. The rising prevalence of cardiovascular diseases, as well as the sheer volume of tests needed worldwide, is the major driver of this market.
Increased research applications, broad target populations, applications in point-of-care testing, and increased global health-care awareness, especially in developing countries, are all positively impacting the market. Researchers’ development of novel strategies for studying the concentration of C-reactive protein offers high-value market growth opportunities.
Key Trends Observed in the C-reactive Protein Testing Market
The C-reactive protein testing market is being boosted by government initiatives to encourage the use of POC (point-of-care) testing in healthcare settings. Point-of-care testing methods have exploded in popularity in recent years, owing to their ability to produce quick and precise results in a short amount of time. Furthermore, the advancement of innovative techniques for measuring C-reactive protein concentrations opens up new opportunities for the C-reactive protein research industry to expand.
For instance, in November 2019, researchers developed an impermanent smartphone-based diffusometric immunoassay for determining the C-reactive protein test. The growing prevalence of gastrointestinal diseases along with the subsequent rise in demand for robust disease testing protocols contributes to the market growth to a considerable extent.
Regional Outlook of C-reactive Protein Testing Market
North America dominates the market owing to the existence of a favorable reimbursement scheme and increasing healthcare expenditure along with rising investment for research activities. For instance, BlueCross BlueShield of North Carolina covers reimbursement for general inflammation testing and provides C-reactive protein testing for the diagnosis of inflammatory diseases.
C-reactive protein is useful in identifying bacterial and non-bacterial infections in ongoing studies in Southeast Asian countries, and it can be used as a biomarker to guide antibiotic prescriptions. In low-malaria transmission countries in Southeast Asia, a combination of the malaria-CRP test is thus considered a feasible alternative to a malaria-only test.
Cardiovascular Diseases (CVD) holds the Highest Revenue Share in the Market
The rising incidence of CVD around the world is one of the major factors that drive demand for C-reactive protein testing. As per the report of the American Heart Association, over 356,000 out-of-hospital cardiac arrest incidences detected in the United States each year, with 90 percent of cases resulting in death. Because of the high occurrence rate, physicians are encouraged to use C-reactive protein testing on a wide scale.
Furthermore, the rise in CVD cases prompts researchers to perform a slew of investigational studies to look into the function of C-reactive protein testing in CVD, boosting segment revenue. For instance, according to a study published by Wei Wang in August 2019, the ratio of hs-CRP to prealbumin can be used as an early biomarker to predict in-hospital significant adverse cardiac events in patients.
Deep-dive Insights on C-reactive Protein Testing Market by Polaris Market Research: https://www.polarismarketresearch.com/industry-analysis/c-reactive-protein-testing-market/request-for-sample